Piperacillin/tazobactam Treatment of 34 Inpatients with Lower Respiratory Tract Infection

OBJECTIVE To evaluate the efficacy and safety of piperacillin/tazobactam in the treatment of inpatients with lower respiratory tract infection. METHODS To observe patients′ clinical manifestation, pulmonary signs, laboratory results, chest X ray films, bacterial culture changes and possible adverse reactions of dermis, neuropsychic system, cardiovascular system and urinary system after intravascular administration of piperacillin/tazobactam. RESULTS The effective rate and the cure rate were 91.2% and 61.8%, respectively, the bacterial eradication rate was 82.1%, the rate of adverse reactions was 5.9%, there were no abnormal laboratory finding. CONCLUSIONS Piperacillin/tazobactam had good efficacy and mild adverse reactions in the treatment of inpatients with lower respiratory tract infection.